Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- KeyBioscience AG
- Target Recruit Count
- 600
- Registration Number
- NCT06833749
- Locations
- 🇨🇿
Pratia Pardubice a.s., Pardubice, Czech Republic
🇨🇿Affidea Praha s.r.o, Prague, Czech Republic
🇨🇿Pratia Prague, s.r.o, Prague, Czech Republic
A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM
Phase 1
Terminated
- Conditions
- Type II Diabetes Mellitus
- Interventions
- Drug: Daily injection of KBP/placebo for up to 28 days
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- KeyBioscience AG
- Target Recruit Count
- 25
- Registration Number
- NCT03907202
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Daily injection of KBP/placebo for 12 weeks as add-on to metformin
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- KeyBioscience AG
- Target Recruit Count
- 255
- Registration Number
- NCT03230786
- Locations
- 🇩🇰
Holbæk Sygehus, Holbæk, Denmark
🇵🇱Centrum Badań Klinicznych PI-House sp. z o.o., Gdańsk, Poland
🇨🇿Diabetologická a Obezitologická ambulance, České Budějovice, Czechia
© Copyright 2025. All Rights Reserved by MedPath